Astrazeneca Pharmaceuticals, Lp

IMJUDO

Manufacturer:

Astrazeneca Pharmaceuticals, Lp

Imjudo HCPCS:

J9347

HCPCS Code Descriptor:

Injection, tremelimumab-actl, 1 mg

Category:

J Code

Imjudo NDCs:

00310-4535-30, 00310-4505-25

Primary Type:

Oncology

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Imjudo:

IMJUDO is a Oncology drug manufactured by Astrazeneca Pharmaceuticals, Lp and administered via the Intravenous route of administration. The J Code: J9347 is aligned to the drug IMJUDO.

IMJUDO is a cancer medication that is under the class of drugs known as Anti-CTLA-4 monoclonal antibodies. This medication binds to the CTLA-4 protein to help the immune system target cancer cells. IMJUDO is used to treat certain types of lung cancer. This drug is manufactured by Astrazeneca pharmaceuticals and is aligned to the HCPCS code J9347. Patient assistance programs can be found through Astrazeneca’s Access 360 and their AZ&Me Prescription Savings Program.

ACCESS PRICING AND MORE BY REGISTERING

J9347 Added Date:

July 1, 2023

J9347 Effective Date:

July 1, 2023

J9347 Termination Date:

HCPCS Active

Imjudo billing and coding information can be found through Astrazeneca Pharmaceuticals, Lp at the link below:
Imjudo patient assistance information can be found through AstraZeneca Access 360 at the URL: https://www.myaccess360.com/home.html
IMJUDO prescribing information can be found at the link below:
Information regarding IMJUDO’s side effects can be found at MedlinePlus